He succeeds Herbert Heyneker, the first investor of the company. He retires as Chair, but will stay as strategic advisor to Mimetas.

Patel is Executive Vice President and Chief Scientific Officer at UCB, Belgium, clinical professor at the University of North Carolina Chapel Hill, and former Head of Research for the Novartis Institutes for BioMedical Research Europe. Since 2021, Mimetas has engaged in a partnership strategy, focusing on disease model development and compound screening based on its proprietary high-throughput organ-on-a-chip platform. “Mimetas is one of those rare companies that will change how we develop medicines,” said Dhaval Patel. “Our unique human disease models will allow the discovery of novel targets and drugs for current and future unmet medical needs. I am excited to join this driven, highly talented team in moving this ambition forward.”